Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q3 EPS of ($0.13), $0.08 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $9.6 million versus the consensus estimate of $16.06 million.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.